MedTrace Logo

Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

NCT04622891 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-11-10

No results posted yet for this study

Summary

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Conditions

  • Covid19

Interventions

DRUG

Clarithromycin 500mg

clarithromycin 500

DRUG

Azithromycin

azithromycin group

DRUG

Placebo

control group

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Alaa Rashad, MD · associate professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-07-30
Completion
2020-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622891 on ClinicalTrials.gov